Advanced search
Publication Cover
Acta Orthopaedica Volume 88, 2017 - Issue 3
Journal homepage
1,192
Views
21
CrossRef citations to date
0
Altmetric
Case Reports

Atypical femoral fractures mimicking metastatic lesions in 2 patients taking denosumab

Daniel C AustinDepartment of Orthopaedic Surgery, Dartmouth Hitchcock Medical Center, Lebanon, NH, USA.Correspondence[email protected]
,
Michael T TorchiaDepartment of Orthopaedic Surgery, Dartmouth Hitchcock Medical Center, Lebanon, NH, USA.
,
Christian M KlareDepartment of Orthopaedic Surgery, Dartmouth Hitchcock Medical Center, Lebanon, NH, USA.
&
Robert V CantuDepartment of Orthopaedic Surgery, Dartmouth Hitchcock Medical Center, Lebanon, NH, USA.
Pages 351-353 | Received 19 Sep 2016, Accepted 11 Nov 2016, Published online: 12 Jan 2017

  • Bone H G, Chapurlat R, Brandi M, Brown J P, Czerwinski E, Krieg M A, Mellstrom D, Radominski S C, Reginster J Y, Resch H, Ivorra JA, Roux C, Vittinghoff E, Daizadeh N S, Wang A, Bradley M N, Franchimont N, Geller M L, Wagman R B, Cummings S R, Papapoulos S. The effect of three or six years of denosumab exposure in women with postmenopausal osteoporosis: Results from the FREEDOM extension. J Clin Endocrinol Metab 2013; 98(11): 4483–92.
  • Chang S T, Tenforde A S, Grimsrud C D, O’Ryan F S, Gonzalez J R, Baer D M, Chandra M, Lo J C. Atypical femur fractures among breast cancer and multiple myeloma patients receiving intravenous bisphosphonate therapy. Bone 2012; 51(3): 524–7.
  • Cummings S R, Martin J S, McClung M R, Siris E S, Eastell R, Reid I R, Delmas P, Zoog H B, Austin M, Wang A, Kutilek S, Adami S, Zanchetta J, Libanati C, Siddhanti S, Christiansen C, FREEDOM Trial. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009; 361(8): 756–65.
  • Drake M T, Clarke B L, Khosla S. Bisphosphonates: Mechanism of action and role in clinical practice. Mayo Clin Proc 2008; 83(9): 1032–45.
  • Drampalos E, Skarpas G, Barbounakis N, Michos I. Atypical femoral fractures bilaterally in a patient receiving denosumab. Acta Orthop 2014; 85(1): 3–5.
  • Khow K S F, Yong T Y. Atypical femoral fracture in a patient treated with denosumab. J Bone Miner Metab 2015; 33(3): 355–8.
  • Koeppen V A, Schilcher J, Aspenberg P. Dichotomous location of 160 atypical femur fractures. Acta Orthop 2013; 84(6): 561–4.
  • Lipton A, Fizazi K, Stopeck A T, Henry D H, Smith M R, Shore N, Martin M, Vadhan-Raj S, Brown J E, Richardson G E, Saad F, Yardley D A, Zhou K, Balakumaran A, Braun A. Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: A combined analysis of 3 pivotal, randomised, phase 3 trials. Eur J Cancer 2012; 48(16): 3082–92.
  • Mashiba T, Hirano T, Turner C H, Forwood M R, Johnston C C, Burr D B. Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib. J Bone Miner Res 2000; 15(4): 613–20.
  • Papapoulos S, Lippuner K, Roux C, Lin C J, Kendler D L, Lewiecki E M, Brandi M L, Czerwinski E, Franek E, Lakatos P, Mautalen C, Minisola S, Reginster J Y, Jensen S, Daizadeh N S, Wang A, Gavin M, Libanati C, Wagman R B, Bone H G. The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: Results from the FREEDOM extension study. Osteoporos Int 2015; 26(12): 2773–83.
  • Paparodis R, Buehring B, Pelley E, Binkley N. A case of an unusual subtrochanteric fracture in a patient receiving denosumab. Endocr Pract 2013; 19(3): e64–e68.
  • Puhaindran M E, Farooki A, Steensma M R, Hameed M, Healey J H, Boland P J. Atypical subtrochanteric femoral fractures in patients with skeletal malignant involvement treated with intravenous bisphosphonates. J Bone Joint Surg Am 2011; 93(13): 1235–42.
  • Rizzoli R, Yasothan U, Kirkpatrick P. Denosumab. Nat Rev Drug Discov 2010; 9(8): 591–2.
  • Schilcher J, Aspenberg P. Atypical fracture of the femur in a patient using denosumab–a case report. Acta Orthop 2014; 85(1): 6–7.
  • Schilcher J, Koeppen V, Aspenberg P, Michaëlsson K. Risk of atypical femoral fracture during and after bisphosphonate use: Full report of a nationwide study. Acta Orthop 2015; 86(1): 100–7.
  • Selga J, Nuñez J, Minguell J, Lalanza M, Garrido M. Simultaneous bilateral atypical femoral fracture in a patient receiving denosumab: Case report and literature review. Osteoporos Int 2016; 27(2): 827–32.
  • Shane E, Burr D, Abrahamsen B, Adler RA, Brown TD, Cheung AM, Cosman F, Curtis JR, Dell R, Dempster DW, Ebeling PR, Einhorn, Genant HK, Geusens P, Klaushofer K, Lane JM, McKiernan F, McKinney R, Ng A, Nieves J, O’Keefe R, Papapoulous S, Howe TS, van der Meulen MC, Weinstein RS. Atypical subtrochanteric and diaphyseal femoral fractures: Second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2014; 29(1): 1–23.
  • Thompson R N, Armstrong C L, Heyburn G. Bilateral atypical femoral fractures in a patient prescribed denosumab—a case report. Bone 2014; 61: 44–7.
  • Villiers J, Clark D W, Jeswani T, Webster S, Hepburn A L. An atraumatic femoral fracture in a patient with rheumatoid arthritis and osteoporosis treated with denosumab. Case Rep Rheumatol 2013; 2013: 249872.
  • Visekruna M, Wilson D, McKiernan F E. Severely suppressed bone turnover and atypical skeletal fragility. J Clin Endocrinol Metab 2008; 93(8): 2948–52.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.